MA37929B1 - Composés bis(fluoroalkyl) -1,4-benzodiazépinones en tant qu'inhibiteurs de notch - Google Patents
Composés bis(fluoroalkyl) -1,4-benzodiazépinones en tant qu'inhibiteurs de notchInfo
- Publication number
- MA37929B1 MA37929B1 MA37929A MA37929A MA37929B1 MA 37929 B1 MA37929 B1 MA 37929B1 MA 37929 A MA37929 A MA 37929A MA 37929 A MA37929 A MA 37929A MA 37929 B1 MA37929 B1 MA 37929B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- fluoroalkyl
- bis
- notch inhibitors
- benzodiazepinone compounds
- Prior art date
Links
- 125000003709 fluoroalkyl group Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000005650 Notch Receptors Human genes 0.000 abstract 1
- 108010070047 Notch Receptors Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
- C07D243/26—Preparation from compounds already containing the benzodiazepine skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
L'invention concerne des composés de formule (i) et/ou des sels de ceux-ci : formule (i) dans laquelle r1 représente ch2ch2cf3; r2 représente ch2ch2cf3ou ch2ch2ch2cf3; r3 représente h, ch3, ou rx; r4 représente h ou ry; le cycle a représente phényle ou pyridinyle ; et rx, ry, ra, rb, y et z sont tels que définis dans la description. L'invention concerne également des méthodes d'utilisation desdits composés pour inhiber le récepteur notch, et des compositions pharmaceutiques comprenant ces composés. Ces composés sont utiles dans le traitement, la prévention ou le ralentissement de la progression de maladies ou de troubles dans divers domaines thérapeutiques, comme le cancer ; ou en tant que promédicaments desdits composés.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261703912P | 2012-09-21 | 2012-09-21 | |
PCT/US2013/060790 WO2014047372A1 (fr) | 2012-09-21 | 2013-09-20 | Composés bis(fluoroalkyl) -1,4-benzodiazépinones en tant qu'inhibiteurs de notch |
Publications (2)
Publication Number | Publication Date |
---|---|
MA37929A1 MA37929A1 (fr) | 2018-06-29 |
MA37929B1 true MA37929B1 (fr) | 2018-09-28 |
Family
ID=49263506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37929A MA37929B1 (fr) | 2012-09-21 | 2013-09-20 | Composés bis(fluoroalkyl) -1,4-benzodiazépinones en tant qu'inhibiteurs de notch |
Country Status (34)
Country | Link |
---|---|
US (2) | US8999918B2 (fr) |
EP (1) | EP2897945B1 (fr) |
JP (1) | JP6165255B2 (fr) |
KR (1) | KR102155588B1 (fr) |
CN (1) | CN104703976B (fr) |
AR (1) | AR093767A1 (fr) |
AU (1) | AU2013317923B2 (fr) |
BR (1) | BR112015005817B1 (fr) |
CA (1) | CA2885574C (fr) |
CL (1) | CL2015000711A1 (fr) |
CO (1) | CO7310522A2 (fr) |
CY (1) | CY1118739T1 (fr) |
DK (1) | DK2897945T3 (fr) |
EA (1) | EA027281B1 (fr) |
ES (1) | ES2617591T3 (fr) |
HR (1) | HRP20170352T8 (fr) |
HU (1) | HUE032038T2 (fr) |
IL (1) | IL237782A (fr) |
LT (1) | LT2897945T (fr) |
MA (1) | MA37929B1 (fr) |
MX (1) | MX367474B (fr) |
MY (1) | MY185233A (fr) |
NZ (1) | NZ707171A (fr) |
PE (1) | PE20150622A1 (fr) |
PH (1) | PH12015500414A1 (fr) |
PL (1) | PL2897945T3 (fr) |
PT (1) | PT2897945T (fr) |
RS (1) | RS55779B1 (fr) |
SG (1) | SG11201501573UA (fr) |
SI (1) | SI2897945T1 (fr) |
TN (1) | TN2015000102A1 (fr) |
TW (1) | TWI614238B (fr) |
UY (1) | UY35041A (fr) |
WO (1) | WO2014047372A1 (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2897946B1 (fr) * | 2012-09-21 | 2016-11-16 | Bristol-Myers Squibb Company | Composés bis(fluoroalkyl)-1,4-benzodiazépinone n-substitués |
JP2015531792A (ja) | 2012-09-21 | 2015-11-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 1,4−ベンゾジアゼピノン化合物のプロドラッグ |
WO2014047397A1 (fr) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Composés de fluoralkyl- et de fluorocycloalkyl-1,4-benzodiazépinone utilisables en tant qu'inhibiteurs du récepteur notch |
WO2014047370A1 (fr) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Composés fluoroalkyl benzodiazépinones |
UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
JP2015534554A (ja) | 2012-09-21 | 2015-12-03 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | アルキル,フルオロアルキル−1,4−ベンゾジアゼピノン化合物 |
EP2897960B1 (fr) | 2012-09-21 | 2016-08-03 | Bristol-Myers Squibb Company | Composés hétérocycliques tricycliques utilisables en tant qu'inhibiteurs du récepteur notch |
US9187434B2 (en) | 2012-09-21 | 2015-11-17 | Bristol-Myers Squibb Company | Substituted 1,5-benzodiazepinones compounds |
US9133139B2 (en) | 2012-09-21 | 2015-09-15 | Bristol-Myers Squibb Company | Fluoroalkyl-1,4-benzodiazepinone compounds |
CN105101968A (zh) | 2013-04-04 | 2015-11-25 | 百时美施贵宝公司 | 治疗增殖性疾病的组合疗法 |
EA033423B1 (ru) | 2015-02-03 | 2019-10-31 | Pfizer | Циклопропанбензофуранилпиридопиразиндионы |
EP3790553A4 (fr) * | 2018-05-06 | 2022-04-20 | Ayala Pharmaceuticals Inc. | Compositions comprenant des inhibiteurs de cd20 et des composés de bisfluoroalkyl-1,4-benzodiazépinone et leurs procédés d'utilisation |
SG11202011041YA (en) * | 2018-05-06 | 2020-12-30 | Ayala Pharmaceuticals Inc | Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof |
JP2021523190A (ja) * | 2018-05-15 | 2021-09-02 | アヤラ ファーマシューティカルズ インコーポレイテッド | 腺様嚢胞癌を治療するためのビスフルオロアルキル−1,4−ベンゾジアゼピノン化合物を含む組成物 |
CA3100202A1 (fr) * | 2018-05-15 | 2019-11-21 | Bristol-Myers Squibb Company | Compositions comprenant des composes de bisfluoroalkyl-1,4-benzodiazepinone et methodes d'utilisation associees |
WO2019226329A1 (fr) * | 2018-05-24 | 2019-11-28 | Ayala Pharmaceuticals Inc. | Compositions comprenant des composés bisfluoroalkyl-1,4-benzodiazépinone et des agents immunothérapeutiques et leurs méthodes d'utilisation |
US20220192984A1 (en) | 2018-10-02 | 2022-06-23 | Frequency Therapeutics, Inc. | Pharmaceutical compositions comprising otic therapeutic agents and related methods |
SG11202111191YA (en) | 2019-04-08 | 2021-11-29 | Frequency Therapeutics Inc | Combination of chir99021 and valproic acid for treating hearing loss |
US20230108536A1 (en) * | 2020-02-16 | 2023-04-06 | Ayala Pharmaceuticals Inc. | Methods of preparing chiral benzodiazepinone derivatives |
WO2022051442A1 (fr) | 2020-09-03 | 2022-03-10 | Bristol-Myers Squibb Company | Polymorphes de composés de bis(fluoroalkyl)-1,4-benzodiazépinone et leurs utilisations |
CN112142629B (zh) * | 2020-10-10 | 2021-09-14 | 西北工业大学 | 3-氨基磺酰基丙氨酸的制备方法 |
EP4008324A1 (fr) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinaisons comprenant un inhibiteur d'une protéine anti-apoptotique, telle que bcl-2, bcl-xl, bclw ou mcl-1, et un inhibiteur de voie de signalisation notch pour le traitement du cancer |
WO2022122667A1 (fr) | 2020-12-07 | 2022-06-16 | Cellestia Biotech Ag | Combinaisons pharmaceutiques pour le traitement du cancer |
CN117794536A (zh) | 2021-06-02 | 2024-03-29 | 塞莱斯蒂亚生物技术股份公司 | 在治疗自身免疫性和炎症性疾病的方法中使用的化合物 |
WO2023079132A1 (fr) | 2021-11-08 | 2023-05-11 | Cellestia Biotech Ag | Combinaisons pharmaceutiques pour le traitement du cancer |
EP4223292A1 (fr) | 2022-02-07 | 2023-08-09 | Cellestia Biotech AG | Combinaisons pharmaceutiques pour le traitement du cancer |
WO2024036097A1 (fr) | 2022-08-12 | 2024-02-15 | Nuvalent, Inc. | Composés d'éther macrocycliques hétéroaromatiques et isotopologues de ceux-ci |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5324726A (en) | 1989-12-18 | 1994-06-28 | Merck & Co., Inc. | Benzodiazepine analogs |
US5852010A (en) | 1996-04-03 | 1998-12-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
JP2000507587A (ja) | 1996-04-03 | 2000-06-20 | メルク エンド カンパニー インコーポレーテッド | ファルネシルタンパク質トランスフェラーゼ阻害剤 |
US6635632B1 (en) | 1996-12-23 | 2003-10-21 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
NZ525513A (en) | 1998-08-07 | 2004-09-24 | Pont Pharmaceuticals Du | Succinoylamino lactams as inhibitors of Abeta protein production |
HRP990246A2 (en) * | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
US6737038B1 (en) * | 1998-11-12 | 2004-05-18 | Bristol-Myers Squibb Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
AU1618000A (en) | 1998-11-12 | 2000-05-29 | Du Pont Pharmaceuticals Company | Use of radioligands to screen inhibitors of amyloid-beta peptide production |
EP1313426A2 (fr) * | 1998-12-24 | 2003-05-28 | Bristol-Myers Squibb Pharma Company | Benzodiazepines succinoylamino utilisees comme inhibiteurs de la production de proteine a-beta |
MXPA01011052A (es) | 1999-04-30 | 2002-11-22 | Univ Michigan | Aplicaciones terapeuticas de benzodiazepinas pro-apoctoticas. |
US6960576B2 (en) | 1999-09-13 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production |
US6503902B2 (en) | 1999-09-13 | 2003-01-07 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production |
CA2387493A1 (fr) | 1999-10-08 | 2001-04-19 | Lorin Andrew Thompson | Amino sulfonamides de lactame utilises comme inhibiteurs de la production de proteine a.beta. |
JP2003520266A (ja) | 2000-01-24 | 2003-07-02 | メルク シャープ エンド ドーム リミテッド | γ−セクレターゼ阻害薬 |
AU2001239791A1 (en) * | 2000-02-17 | 2001-08-27 | Du Pont Pharmaceuticals Company | Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production |
US6495540B2 (en) | 2000-03-28 | 2002-12-17 | Bristol - Myers Squibb Pharma Company | Lactams as inhibitors of A-β protein production |
AU2001251147A1 (en) | 2000-03-31 | 2001-10-15 | Dupont Pharmaceuticals Company | Succinoylamino heterocycles as inhibitors of abeta protein production |
AU2001253090A1 (en) | 2000-04-03 | 2001-10-15 | Bristol-Myers Squibb Pharma Company | Cyclic lactams as inhibitors of abeta protein production |
BR0110051A (pt) | 2000-04-03 | 2004-12-07 | Bristol Myers Squibb Pharma Co | Composto, uso do composto, composição farmacêutica e método de tratamento do mal de alzheimer |
GB0008710D0 (en) | 2000-04-07 | 2000-05-31 | Merck Sharp & Dohme | Therapeutic compounds |
CA2404273A1 (fr) | 2000-04-11 | 2001-10-18 | Bristol-Myers Squibb Pharma Company | Lactames substitues utilises en tant qu'inhibiteurs de production de proteine a.beta. |
WO2001087354A2 (fr) | 2000-05-17 | 2001-11-22 | Bristol-Myers Squibb Pharma Company | Utilisation de radioligands a petites molecules en vue de rechercher des inhibiteurs de production d'amyloide-beta et destine a l'imagerie diagnostique |
GB0012671D0 (en) | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
CA2379445C (fr) | 2000-06-01 | 2007-08-21 | Bristol-Myers Squibb Pharma Company | Lactames substitues par des succinates cycliques en tant qu'inhibiteurs de la production de la proteine .beta. |
US7001901B2 (en) | 2002-08-27 | 2006-02-21 | Bristol-Myers Squibb Company | Tetrazolylpropionamides as inhibitors of Aβ protein production |
PL375860A1 (en) | 2002-09-20 | 2005-12-12 | Arrow Therapeutics Limited | Benzodiazepine derivatives and pharmaceutical compositions containing them |
MXPA05008172A (es) | 2003-02-04 | 2005-10-05 | Hoffmann La Roche | Derivados de malonamida como inhibidores gamma-secretasa. |
GB0312365D0 (en) | 2003-05-30 | 2003-07-02 | Univ Aston | Novel 3-substituted-1, 4-benzodiazepines |
NZ545538A (en) | 2003-09-09 | 2008-12-24 | Hoffmann La Roche | Malonamide derivatives blocking the activity of gama-secretase |
EP1795198A1 (fr) | 2005-12-09 | 2007-06-13 | Hubrecht Laboratorium | Traitement de l'esophage de Barret |
WO2009023453A1 (fr) | 2007-08-14 | 2009-02-19 | Eli Lilly And Company | Dérivés d'azépine en tant qu'inhibiteurs de gamma-sécrétase |
US20090181944A1 (en) | 2008-01-11 | 2009-07-16 | John Frederick Boylan | Method for cancer therapy |
TWI530489B (zh) * | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙(氟烷基)-1,4-苯二氮呯酮化合物 |
EP2897946B1 (fr) * | 2012-09-21 | 2016-11-16 | Bristol-Myers Squibb Company | Composés bis(fluoroalkyl)-1,4-benzodiazépinone n-substitués |
-
2013
- 2013-09-18 TW TW102133985A patent/TWI614238B/zh active
- 2013-09-20 US US14/032,333 patent/US8999918B2/en active Active
- 2013-09-20 DK DK13770806.1T patent/DK2897945T3/en active
- 2013-09-20 AU AU2013317923A patent/AU2013317923B2/en active Active
- 2013-09-20 PL PL13770806T patent/PL2897945T3/pl unknown
- 2013-09-20 BR BR112015005817-5A patent/BR112015005817B1/pt active IP Right Grant
- 2013-09-20 SG SG11201501573UA patent/SG11201501573UA/en unknown
- 2013-09-20 JP JP2015533198A patent/JP6165255B2/ja active Active
- 2013-09-20 PE PE2015000392A patent/PE20150622A1/es active IP Right Grant
- 2013-09-20 PT PT137708061T patent/PT2897945T/pt unknown
- 2013-09-20 EA EA201590581A patent/EA027281B1/ru not_active IP Right Cessation
- 2013-09-20 EP EP13770806.1A patent/EP2897945B1/fr active Active
- 2013-09-20 UY UY0001035041A patent/UY35041A/es active IP Right Grant
- 2013-09-20 MX MX2015003033A patent/MX367474B/es active IP Right Grant
- 2013-09-20 MA MA37929A patent/MA37929B1/fr unknown
- 2013-09-20 WO PCT/US2013/060790 patent/WO2014047372A1/fr active Application Filing
- 2013-09-20 ES ES13770806.1T patent/ES2617591T3/es active Active
- 2013-09-20 KR KR1020157006776A patent/KR102155588B1/ko active IP Right Grant
- 2013-09-20 NZ NZ707171A patent/NZ707171A/en unknown
- 2013-09-20 SI SI201330507A patent/SI2897945T1/sl unknown
- 2013-09-20 RS RS20170259A patent/RS55779B1/sr unknown
- 2013-09-20 AR ARP130103390A patent/AR093767A1/es unknown
- 2013-09-20 HU HUE13770806A patent/HUE032038T2/en unknown
- 2013-09-20 CN CN201380048504.4A patent/CN104703976B/zh active Active
- 2013-09-20 CA CA2885574A patent/CA2885574C/fr active Active
- 2013-09-20 LT LTEP13770806.1T patent/LT2897945T/lt unknown
- 2013-09-20 MY MYPI2015700879A patent/MY185233A/en unknown
-
2015
- 2015-02-20 US US14/627,573 patent/US9273014B2/en active Active
- 2015-02-26 PH PH12015500414A patent/PH12015500414A1/en unknown
- 2015-03-12 CO CO15057524A patent/CO7310522A2/es unknown
- 2015-03-16 IL IL237782A patent/IL237782A/en active IP Right Grant
- 2015-03-17 TN TNP2015000102A patent/TN2015000102A1/fr unknown
- 2015-03-20 CL CL2015000711A patent/CL2015000711A1/es unknown
-
2017
- 2017-03-03 HR HRP20170352TT patent/HRP20170352T8/hr unknown
- 2017-03-16 CY CY20171100338T patent/CY1118739T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA37929B1 (fr) | Composés bis(fluoroalkyl) -1,4-benzodiazépinones en tant qu'inhibiteurs de notch | |
MA35036B1 (fr) | Composés bis(fluoroalkyl)-1,4-benzodiazépinone | |
MA37762A1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
MA42295B1 (fr) | Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation | |
MA38227A1 (fr) | Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase | |
MA47043B1 (fr) | Composés indole carboxamides utiles comme inhibiteurs de kinase | |
MA42410A (fr) | Oxystérols et leurs méthodes d'utilisation | |
MA43979B1 (fr) | Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques | |
MA37891B1 (fr) | Alcoxypyrazoles comme activateurs de guanylate cyclase soluble | |
TN2015000347A1 (fr) | Azabenzimidazoles servant d'inhibiteurs d'isoenzymes pde4 pour le traitement de troubles du snc et d'autres troubles | |
MA37142A3 (fr) | Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine | |
MA38398A1 (fr) | Composés biaryle amides en tant qu'inhibiteurs de kinase | |
MA35576B1 (fr) | Nouveaux composés | |
MA30932B1 (fr) | Spirocetones servant d'inhibiteurs d'acetyl-coa -carboxylase | |
MA35184B1 (fr) | Antagonistes de trpv4 | |
MA37765A1 (fr) | Composés de pyrazole substitués utilisés comme antagonistes de lpar | |
MA37831A1 (fr) | Dérivés d'azaindole agissant comme inhibiteur de pi3k | |
MA31170B1 (fr) | Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer | |
MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
MA38810A1 (fr) | Inhibiteurs de rorc2 méthodes d'utilisation associées | |
MA39165A1 (fr) | Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires | |
MA38425A1 (fr) | Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1 | |
MA31688B1 (fr) | Nouveaux herbicides | |
MA44503B1 (fr) | Composés de pyrrolotriazine en tant qu'inhibiteurs de tam |